Hottest Servier pharmaceutical obtained itca6 thro

2022-08-09
  • Detail

Servier pharmaceutical obtained the patent right of ITCA 650 pump through the agreement

French pharmaceutical company Servier obtained the license through a 67 ~ 93hr15t agreement with a value of US $1billion. With the gradual recovery of the international market, a micro drug loading pump device was developed by intarcia therapeutics. Servier has obtained the right of ITCA 650 pump outside the United States and Japan. When used, ITCA 650 pump is implanted under the skin. It can deliver GLP-1 agonist AI

French pharmaceutical, which provides a certain development opportunity for manufacturers of coatings and adhesives. Servier obtained a micro drug loading pump device developed by intarcia therapeutics through an agreement license worth $1billion. Servier has obtained the right of ITCA 650 pump outside the United States and Japan. When used, ITCA 650 pump is implanted under the skin, which can deliver GLP-1 agonist exenatide. The company said in a statement that the device "may reshape the treatment of type 2 diabetes in the near future."

this matchstick sized osmotic pump will provide continuous administration of the GLP-1 agonist exenatide (which works by improving insulin secretion). The device only needs to be implanted once or twice a year. At present, this device is in the phase 3 trial stage

"qualified doctors, nurses or physician assistants can place ITCA 650 in a simple five minute operation in the doctor's office," the two companies said in a statement. If approved, ITCA 650 will become the first and only GLP-1 therapeutic drug without injection, which can deliver therapeutic drugs for a whole year in a single dose

exenatide is an active ingredient in AstraZeneca's once daily diabetes drug Byetta and once a week diabetes drug bydureon. These two drugs compete with Novo Nordisk's best-selling drug liraglutide and Lilly's just approved dulaglutide in the GLP-1 agonist market with a predicted scale of $3billion

in the two recently reported phase 3 trials, ITCA 650 is superior to placebo in controlling blood glucose in patients with type 2 diabetes, and can significantly improve the efficacy of oral diabetes drugs in patients with diabetes who are not well controlled, helping 25% of these patients reach the target level of glycosylated hemoglobin (HbA1c, a blood glucose control index)

two other phase 3 trials are in progress. If the test results are positive, the regulatory application will be submitted globally in the first half of 2016. Among them, one study is a one-on-one clinical trial with mosartan DPP-4 inhibitor sitagliptin, and the other study is a cardiovascular outcome study

according to the terms of the agreement, intarcia, located in Boston, USA, will receive an advance payment of US $171million, a milestone payment of US $230million at the early stage of the listing application submission, and finally a full payment of US $650million. Intarcia still retains the right of this device in the United States, and the company said it was seeking permission for the device in Japan

although Servier does sell a series of products based on the sulfonylurea drug gliclazide, and there are many research projects, in terms of absolute sales, the company is a relatively small company in the field of diabetes, so inta's decision to improve transparency and governance RCIA is in line with its own situation, unlike Sanofi, AstraZeneca, Novo Nordisk MSD or Lilly did something amazing like that

however, graves, CEO of the US biotech company, said that although the company had negotiated with less than 11 other pharmaceutical companies on the rights of ITCA 650, only Servier agreed that it would fully retain the rights of the project in the United States

Copyright © 2011 JIN SHI